Polianta Ltd Takes Position in Icon Plc $ICLR

Polianta Ltd purchased a new stake in shares of Icon Plc (NASDAQ:ICLR) in the second quarter, HoldingsChannel.com reports. The firm purchased 10,800 shares of the medical research company’s stock, valued at approximately $1,876,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Sanctuary Advisors LLC boosted its position in Icon by 1.1% in the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after buying an additional 56 shares during the last quarter. Geneos Wealth Management Inc. increased its position in shares of Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Icon by 21.4% in the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after acquiring an additional 69 shares in the last quarter. Signaturefd LLC boosted its holdings in Icon by 12.6% in the fourth quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 72 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its holdings in Icon by 0.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock valued at $4,363,000 after purchasing an additional 93 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Price Performance

ICLR opened at $164.51 on Friday. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. The company’s 50-day moving average price is $160.35 and its 200 day moving average price is $134.86. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $203.91. The firm has a market cap of $12.60 billion, a price-to-earnings ratio of 38.62, a price-to-earnings-growth ratio of 6.82 and a beta of 1.21.

Icon (NASDAQ:ICLR) last posted its earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.55 by $0.01. The company had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.The business’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company earned $3.26 earnings per share. As a group, sell-side analysts expect that Icon Plc will post 9.57 earnings per share for the current year.

Analyst Ratings Changes

ICLR has been the topic of several analyst reports. Piper Sandler downgraded Icon to a “neutral” rating in a report on Thursday, May 28th. TD Cowen increased their target price on Icon from $164.00 to $197.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Robert W. Baird set a $194.00 price target on shares of Icon in a research report on Friday, July 31st. Weiss Ratings lowered shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 29th. Finally, Zacks Research raised shares of Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $170.40.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.